Citations

Clear

4206 citation(s) found for "Yu, Chen".

Tokyo Guidelines 2018: flowchart for the management of acute cholecystitis
Okamoto, Kohji , Takada, Tadahiro , Strasberg, Steven M. , Asbun, Horacio J. , Endo, Itaru , Iwashita, Yukio , Hibi, Taizo , Pitt, Henry A. , Umezawa, Akiko , Asai, Koji , Hwang, Tsann‐Long , Mori, Yasuhisa , Huang, Wayne Shih‐Wei, Belli, Giulio, Dervenis, Christos, Yokoe, Masamichi, Kiriyama, Seiki , Itoi, Takao , Jagannath, P., Garden, O. James , Miura, Fumihiko, Wakabayashi, Go , Cherqui, Daniel , Santibáñes, Eduardo de , Shikata, Satoru , Noguchi, Yoshinori , Higuchi, Ryota , Wada, Keita, Supe, Avinash , Yoshida, Masahiro , Mayumi, Toshihiko , Gouma, Dirk J., Deziel, Daniel J., Liau, Kui‐Hin, Chen, Miin‐Fu , Shibao, Kazunori , Liu, Keng‐Hao, Su, Cheng‐Hsi, Chan, Angus C. W., Choi, In‐Seok , Jonas, Eduard , Fan, Sheung Tat , Ker, Chen‐Guo , Giménez, Mariano , Kitano, Seigo, Inomata, Masafumi , Inui, Kazuo, Sumiyama, Yoshinobu, Yamamoto, Masakazu , Suzuki, Kenji S. , Han, Ho-Seong , Yoon, Yoo-Seok , Nakamura, Masafumi , Horiguchi, Akihiko , Ukai, Tomohiko , Honda, Goro , Yoon, Dong Sup , Chen, Xiaoping , Hirata, Koichi , Jonas, Eduard

Mayo Clinic

Journal of Hepato-Biliary-Pancreatic Sciences | October 16, 2017 | Volume: 25 | Issue: 1 | Pages: 55-72

10.1002/jhbp.516 | PMID 29045062 Get It

Abstract We propose a new flowchart for the treatment of acute cholecystitis ( AC ) in the Tokyo Guidelines 2018 (TG18). Grade III AC was not indicated for straightforward laparoscopic cholecystectomy (Lap‐C). Following analysis of subsequent clinical investigations and drawing on Big Data in particular, TG 18 proposes that some Grade III AC can be treated by Lap‐C when performed at advanced centers with specialized surgeons experienced in this procedure and for patients that satisfy certain strict criteria. For Grade I, TG 18 recommends early Lap‐C if the patients meet the criteria of Charlson comorbidity index ( CCI ) ≤5 and American Society of Anesthesiologists physical status classification ( ASA ‐ PS ) ≤2. For Grade II AC , if patients meet the criteria of CCI ≤5 and ASA ‐ PS ≤2, TG 18 recommends early Lap‐C performed by experienced surgeons; and if not, after medical treatment and/or gallbladder drainage, Lap‐C would be indicated. TG 18 proposes that Lap‐C is indicated in Grade III patients with strict criteria. These are that the patients have favorable organ system failure, and negative predictive factors, who meet the criteria of CCI ≤3 and ASA ‐ PS ≤2 and who are being treated at an advanced center (where experienced surgeons practice). If the patient is not considered suitable for early surgery, TG 18 recommends early/urgent biliary drainage followed by delayed Lap‐C once the patient's overall condition has improved. Free full articles and mobile app of TG18 are available at: http://www.jshbps.jp/modules/en/index.php?content_id=47 . Related clinical questions and references are also included.
Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholecystitis (with videos)
Yokoe, Masamichi, Hata, Jiro , Takada, Tadahiro , Strasberg, Steven M. , Asbun, Horacio J. , Wakabayashi, Go , Kozaka, Kazuto , Endo, Itaru , Deziel, Daniel J., Miura, Fumihiko, Okamoto, Kohji , Hwang, Tsann‐Long , Huang, Wayne Shih‐Wei, Ker, Chen‐Guo , Chen, Miin‐Fu , Choi, In‐Seok , Noguchi, Yoshinori , Shikata, Satoru , Higuchi, Ryota , Gabata, Toshifumi , Mori, Yasuhisa , Iwashita, Yukio , Hibi, Taizo , Jagannath, P., Jonas, Eduard , Liau, Kui‐Hin, Dervenis, Christos, Gouma, Dirk J., Cherqui, Daniel , Belli, Giulio, Garden, O. James , Giménez, Mariano , Santibáñes, Eduardo de , Umezawa, Akiko , Supe, Avinash , Pitt, Henry A. , Singh, Harjit , Chan, Angus C. W., Lau, Wan Yee , Sugioka, Atsushi , Asai, Koji , Gomi, Harumi , Itoi, Takao , Kiriyama, Seiki , Yoshida, Masahiro , Mayumi, Toshihiko , Matsumura, Naoki , Tokumura, Hiromi, Kitano, Seigo, Inui, Kazuo, Sumiyama, Yoshinobu, Yamamoto, Masakazu , Han, Ho-Seong , Yoon, Yoo-Seok , Yoon, Dong Sup , Ukai, Tomohiko , Suzuki, Kenji S. , Teoh, Anthony Yuen Bun , Honda, Goro , Hirata, Koichi , Jonas, Eduard

Mayo Clinic

Journal of Hepato-Biliary-Pancreatic Sciences | October 15, 2017 | Volume: 25 | Issue: 1 | Pages: 41-54

10.1002/jhbp.515 | PMID 29032636 Get It

Abstract The Tokyo Guidelines 2013 (TG13) for acute cholangitis and cholecystitis were globally disseminated and various clinical studies about the management of acute cholecystitis were reported by many researchers and clinicians from all over the world. The 1 st edition of the Tokyo Guidelines 2007 ( TG 07) was revised in 2013. According to that revision, the TG 13 diagnostic criteria of acute cholecystitis provided better specificity and higher diagnostic accuracy. Thorough our literature search about diagnostic criteria for acute cholecystitis, new and strong evidence that had been released from 2013 to 2017 was not found with serious and important issues about using TG 13 diagnostic criteria of acute cholecystitis. On the other hand, the TG 13 severity grading for acute cholecystitis has been validated in numerous studies. As a result of these reviews, the TG 13 severity grading for acute cholecystitis was significantly associated with parameters including 30‐day overall mortality, length of hospital stay, conversion rates to open surgery, and medical costs. In terms of severity assessment, breakthrough and intensive literature for revising severity grading was not reported. Consequently, TG 13 diagnostic criteria and severity grading were judged from numerous validation studies as useful indicators in clinical practice and adopted as TG 18/ TG 13 diagnostic criteria and severity grading of acute cholecystitis without any modification. Free full articles and mobile app of TG18 are available at: http://www.jshbps.jp/modules/en/index.php?content_id=47 . Related clinical questions and references are also included.
Low‐dose CT for the detection and classification of metastatic liver lesions: Results of the 2016 Low Dose CT Grand Challenge
Bartley, Adam C. , Carter, Rickey E. , Chen, Baiyu , Drees, Tammy A., Edwards, Phillip K , Holmes, David R. , Huang, Alice E. , Khan, Farhana, McMillan, Kyle, Michalak, Gregory J. , Nunez, Kristina M., Yu, Lifeng , Edwards, Phillip, McMillan, Kyle L, Carter, Rickey E , McCollough, Cynthia H. , Leng, Shuai , Yu, Lifeng , Fletcher, Joel G.

Mayo Clinic

Medical Physics | October 13, 2017 | Volume: 44 | Issue: 10 | Pages: No page available

10.1002/mp.12345 | PMID 29027235 Get It

Purpose Using common datasets, to estimate and compare the diagnostic performance of image‐based denoising techniques or iterative reconstruction algorithms for the task of detecting hepatic metastases. Methods Datasets from contrast‐enhanced CT scans of the liver were provided to participants in an NIH ‐, AAPM ‐ and Mayo Clinic‐sponsored Low Dose CT Grand Challenge. Training data included full‐dose and quarter‐dose scans of the ACR CT accreditation phantom and 10 patient examinations; both images and projections were provided in the training data. Projection data were supplied in a vendor‐neutral standardized format ( DICOM ‐ CT ‐ PD ). Twenty quarter‐dose patient datasets were provided to each participant for testing the performance of their technique. Images were provided to sites intending to perform denoising in the image domain. Fully preprocessed projection data and statistical noise maps were provided to sites intending to perform iterative reconstruction. Upon return of the denoised or iteratively reconstructed quarter‐dose images, randomized, blinded evaluation of the cases was performed using a Latin Square study design by 11 senior radiology residents or fellows, who marked the locations of identified hepatic metastases. Markings were scored against reference locations of clinically or pathologically demonstrated metastases to determine a per‐lesion normalized score and a per‐case normalized score (a faculty abdominal radiologist established the reference location using clinical and pathological information). Scores increased for correct detections; scores decreased for missed or incorrect detections. The winner for the competition was the entry that produced the highest total score (mean of the per‐lesion and per‐case normalized score). Reader confidence was used to compute a Jackknife alternative free‐response receiver operating characteristic ( JAFROC ) figure of merit, which was used for breaking ties. Results 103 participants from 90 sites and 26 countries registered to participate. Training data were shared with 77 sites that completed the data sharing agreements. Subsequently, 41 sites downloaded the 20 test cases, which included only the 25% dose data ( CTDI vol = 3.0 ± 1.8 mG y, SSDE = 3.5 ± 1.3 mG y). 22 sites submitted results for evaluation. One site provided binary images and one site provided images with severe artifacts; cases from these sites were excluded from review and the participants removed from the challenge. The mean (range) per‐lesion and per‐case normalized scores were −24.2% (−75.8%, 3%) and 47% (10%, 70%), respectively. Compared to reader results for commercially reconstructed quarter‐dose images with no noise reduction, 11 of the 20 sites showed a numeric improvement in the mean JAFROC figure of merit. Notably two sites performed comparably to the reader results for full‐dose commercial images. The study was not designed for these comparisons, so wide confidence intervals surrounded these figures of merit and the results should be used only to motivate future testing. Conclusion Infrastructure and methodology were developed to rapidly estimate observer performance for liver metastasis detection in low‐dose CT examinations of the liver after either image‐based denoising or iterative reconstruction. The results demonstrated large differences in detection and classification performance between noise reduction methods, although the majority of methods provided some improvement in performance relative to the commercial quarter‐dose images with no noise reduction applied.
Lactic Acid: No Longer an Inert and End-Product of Glycolysis
Sun, Shiren , Chen, Jianghua , Qian, Qi , Li, Heng

Mayo Clinic

Physiology | October 12, 2017 | Volume: 32 | Issue: 6 | Pages: 453-463

10.1152/physiol.00016.2017 | PMID 29021365 Get It

For decades, lactic acid has been considered a dead-end product of glycolysis. Research in the last 20+ years has shown otherwise. Through its transporters (MCTs) and receptor (GPR81), lactic acid plays a key role in multiple cellular processes, including energy regulation, immune tolerance, memory formation, wound healing, ischemic tissue injury, and cancer growth and metastasis. We summarize key findings of lactic acid signaling, functions, and many remaining questions.
An omnibus test for differential distribution analysis of microbiome sequencing data
King, Emily A. , Deek, Rebecca A. , Wei, Zhi , Grill, Diane E. , Chen, Jun , Yu, Yue , Ballman, Karla V. , Wei, Zhi

Mayo Clinic

Bioinformatics | October 11, 2017 | Volume: 34 | Issue: 4 | Pages: 643-651

10.1093/bioinformatics/btx650 | PMID 29040451 Get It

AbstractMotivationOne objective of human microbiome studies is to identify differentially abundant microbes across biological conditions. Previous statistical methods focus on detecting the shift in the abundance and/or prevalence of the microbes and treat the dispersion (spread of the data) as a nuisance. These methods also assume that the dispersion is the same across conditions, an assumption which may not hold in presence of sample heterogeneity. Moreover, the widespread outliers in the microbiome sequencing data make existing parametric models not overly robust. Therefore, a robust and powerful method that allows covariate-dependent dispersion and addresses outliers is still needed for differential abundance analysis.ResultsWe introduce a novel test for differential distribution analysis of microbiome sequencing data by jointly testing the abundance, prevalence and dispersion. The test is built on a zero-inflated negative binomial regression model and winsorized count data to account for zero-inflation and outliers. Using simulated data and real microbiome sequencing datasets, we show that our test is robust across various biological conditions and overall more powerful than previous methods.Availability and implementationR package is available at https://github.com/jchen1981/MicrobiomeDDA.Supplementary informationSupplementary data are available at Bioinformatics online.
The Influence of Tumor Stage on the Prognostic Value of Ki-67 Index and Mitotic Count in Small Intestinal Neuroendocrine Tumors
Sun, Yu , Lohse, Christine M. , Smyrk, Thomas C. , Hobday, Timothy J. , Kroneman, Trynda, Zhang, Lizhi , Hobday, Timothy

Mayo Clinic

American Journal of Surgical Pathology | October 10, 2017 | Volume: 42 | Issue: 2 | Pages: 247-255

10.1097/pas.0000000000000968 | PMID 29016403 Get It

Tumor cell proliferation rate determined by either Ki-67 index or mitotic count (MC) has shown to be a prognostic factor for gastrointestinal neuroendocrine tumors in general, and after its incorporation in the 2010 World Health Organization tumor grading system, it has become essentially mandatory in pathology reports for all gastrointestinal neuroendocrine tumors, regardless of tumor location. Nevertheless, clinical significance for the Ki-67 index or MC has not been well demonstrated in small intestinal neuroendocrine tumor (SINET), especially those without distant metastasis, the majority of which have very low proliferation rates. We assessed the clinical behavior of 130 SINETs in relation to stage, Ki-67 index, MC, and other pathologic features. Most SINETs (86%) were grade 1 and 14% were grade 2. There were no grade 3 tumors or poorly differentiated neuroendocrine carcinomas. On multivariate analysis, age, Ki-67 index >5%, MC >10/50 high-power field, stage IV, and liver metastases were associated with increased risk of death in all patients. When both stage and grade were considered, Ki-67 index >5% was associated with a nearly 4-fold increased risk of death in stage IV cases (n=60). In contrast, Ki-67 index did not show prognostic value for patients with stages I to III disease (n=70), although MC >1/50 high-power field was significantly associated with death on multivariable analysis. Our study confirms that liver metastasis and increased tumor cell proliferation rate are independent prognostic factors for SINETs, but shows that most SINETs have a very low proliferation rate, which limits its value for predicting tumor behavior. By combining staging and grading information, we demonstrate different roles and cutoff values of Ki-67 index and MC in SINET with different stages.
Behavioral and transcriptomic analysis of Trem2-null mice: not all knockout mice are created equal
Kang, Silvia S. , Kurti, Aishe, Baker, Kelsey E., Liu, Chia‐Chen , Ulrich, Jason D. , Bu, Guojun , Fryer, John Denis , Fryer, John D., Liu, Chia-Chen , Bu, Guojun , Colonna, Marco , Holtzman, David M.

Mayo Clinic

Human Molecular Genetics | October 10, 2017 | Volume: 27 | Issue: 2 | Pages: 211-223

10.1093/hmg/ddx366 | PMID 29040522 Get It

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
Chesney, Jason , Collichio, Frances A. , Milhem, Mohammed , Hamid, Omid , Ross, Merrick I. , Friedlander, Philip , Garbe, Claus , Logan, Theodore F. , Chen, Lisa , Gansert, Jennifer, Andtbacka, Robert H.I. , Singh, Parminder , Collichio, Frances, Milhem, Mohammed M, Glaspy, John, Ross, Merrick, Hauschild, Axel, Lebbe, Celeste, Kim, Jenny J, Kaufman, Howard L, Milhem, Mohammed M , Puzanov, Igor , Singh, Parminder Pal , Glaspy, John A. , Hauschild, Axel , Lebbé, Célèste , Kim, Jaeyeon , Kaufman, Howard L. , Singh, Parminder

Mayo Clinic

Journal of Clinical Oncology | October 5, 2017 | Volume: 36 | Issue: 17 | Pages: 1658-1667

10.1200/jco.2017.73.7379 | PMID 28981385 Get It

Purpose We evaluated the combination of talimogene laherparepvec plus ipilimumab versus ipilimumab alone in patients with advanced melanoma in a phase II study. To our knowledge, this was the first randomized trial to evaluate addition of an oncolytic virus to a checkpoint inhibitor. Methods Patients with unresectable stages IIIB to IV melanoma, with no more than one prior therapy if BRAF wild-type, no more than two prior therapies if BRAF mutant, measurable/injectable disease, and without symptomatic autoimmunity or clinically significant immunosuppression were randomly assigned 1:1 to receive talimogene laherparepvec plus ipilimumab or ipilimumab alone. Talimogene laherparepvec treatment began in week 1 (first dose, ≤ 4 mL × 10 6 plaque-forming units/mL; after 3 weeks, ≤ 4 mL × 10 8 plaque-forming units/mL every 2 weeks). Ipilimumab (3 mg/kg every 3 weeks; up to four doses) began week 1 in the ipilimumab alone arm and week 6 in the combination arm. The primary end point was objective response rate evaluated by investigators per immune-related response criteria. Results One hundred ninety-eight patients were randomly assigned to talimogene laherparepvec plus ipilimumab (n = 98), or ipilimumab alone (n = 100). Thirty-eight patients (39%) in the combination arm and 18 patients (18%) in the ipilimumab arm had an objective response (odds ratio, 2.9; 95% CI, 1.5 to 5.5; P = .002). Responses were not limited to injected lesions; visceral lesion decreases were observed in 52% of patients in the combination arm and 23% of patients in the ipilimumab arm. Frequently occurring adverse events (AEs) included fatigue (combination, 59%; ipilimumab alone, 42%), chills (combination, 53%; ipilimumab alone, 3%), and diarrhea (combination, 42%; ipilimumab alone, 35%). Incidence of grade ≥ 3 AEs was 45% and 35%, respectively. Three patients in the combination arm had fatal AEs; none were treatment related. Conclusion The study met its primary end point; the objective response rate was significantly higher with talimogene laherparepvec plus ipilimumab versus ipilimumab alone. These data indicate that the combination has greater antitumor activity without additional safety concerns versus ipilimumab.
Common TDP1 Polymorphisms in Relation to Survival among Small Cell Lung Cancer Patients: A Multicenter Study from the International Lung Cancer Consortium
Lohavanichbutr, Pawadee, Arnold, Susanne M. , Davies, Michael P.A. , Field, John K. , Haura, Eric B. , Hung, Rayjean J., Kohno, Takashi , Landi, Maria Teresa , Liu, Geoffrey , Marcus, Michael W. , O’Kane, Grainne M. , Schabath, Matthew B. , Slone, Stacey , Tardón, Adonina , Yoshida, Kazushi, Zong, Xuchen, Goodman, Gary E. , Chen, Chu , Hung, Rayjean J. , Hung, Rayjean J , Liu, Geoffrey , Field, John K , Tardón, Adonina , Davies, Michael P A , Schabath, Matthew B , Sakoda, Lori C. , Amos, Christopher I. , Christiani, David C. , Liu, Yi , Shiraishi, Kouya , Yang, Ping , Zhang, Ruyang , Weiss, Noel S , Arnold, Susanne M , O'Kane, Grainne M.

Mayo Clinic

Clinical Cancer Research | October 3, 2017 | Volume: 23 | Issue: 24 | Pages: 7550-7557

10.1158/1078-0432.ccr-17-1401 | PMID 28974547 Get It

Abstract Purpose: DNA topoisomerase inhibitors are commonly used for treating small-cell lung cancer (SCLC). Tyrosyl-DNA phosphodiesterase (TDP1) repairs DNA damage caused by this class of drugs and may therefore influence treatment outcome. In this study, we investigated whether common TDP1 single-nucleotide polymorphisms (SNP) are associated with overall survival among SCLC patients. Experimental Design: Two TDP1 SNPs (rs942190 and rs2401863) were analyzed in 890 patients from 10 studies in the International Lung Cancer Consortium (ILCCO). The Kaplan–Meier method and Cox regression analyses were used to evaluate genotype associations with overall mortality at 36 months postdiagnosis, adjusting for age, sex, race, and tumor stage. Results: Patients homozygous for the minor allele (GG) of rs942190 had poorer survival compared with those carrying AA alleles, with a HR of 1.36 [95% confidence interval (CI): 1.08–1.72, P = 0.01), but no association with survival was observed for patients carrying the AG genotype (HR = 1.04, 95% CI, 0.84–1.29, P = 0.72). For rs2401863, patients homozygous for the minor allele (CC) tended to have better survival than patients carrying AA alleles (HR = 0.79; 95% CI, 0.61–1.02, P = 0.07). Results from the Genotype Tissue Expression (GTEx) Project, the Encyclopedia of DNA Elements (ENCODE), and the ePOSSUM web application support the potential function of rs942190. Conclusions: We found the rs942190 GG genotype to be associated with relatively poor survival among SCLC patients. Further investigation is needed to confirm the result and to determine whether this genotype may be a predictive marker for treatment efficacy of DNA topoisomerase inhibitors. Clin Cancer Res; 23(24); 7550–7. ©2017 AACR.
Butyrylcholinesterase gene transfer in obese mice prevents postdieting body weight rebound by suppressing ghrelin signaling
Chen, Vicky Ping , Gao, Yang , Geng, Liyi, Brimijoin, Stephen

Mayo Clinic

Proceedings of the National Academy of Sciences | October 2, 2017 | Volume: 114 | Issue: 41 | Pages: 10960-10965

10.1073/pnas.1706517114 | PMID 28973869 Get It

Significance Obesity is a major public health problem affecting physical and emotional well-being. Although lifestyle-based programs can help with weight loss, avoiding weight regain is nearly impossible because of persistent hormonal adaptations. Here, in mouse models, we explored a more effective strategy using viral gene transfer of butyrylcholinesterase (BChE) to control the appetite-mediating hormone acyl-ghrelin. We found that a single injection of BChE vector led to a lifetime high enzyme expression and lower circulating acyl-ghrelin. This same treatment suppressed postdieting hyperphagia, corrected metabolic lesions, and lowered weight regain. This outcome confirms the impact of the BChE-ghrelin axis on body weight and indicates that BChE gene transfer could be a successful strategy for long-term control of obesity and the “metabolic syndrome.”